Press releases
May 9, 2025
MeiraGTx Secures FDA RMAT Designation for Groundbreaking Parkinson’s Gene Therapy
MeiraGTx has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AAV-GAD, for Parkinson’s disease.